SLNO (MC $24 M) Rare Disease in Phase 3 a Potential Blockbuster =MASSIVE Undervalued

Discussion in 'Stock picks and trading strategies' started by DollarChamp, Aug 31, 2017.

  1. DollarChamp

    DollarChamp Member

    Soleno (SLNO) is a new formed company through the merger between Capnia and the private Essentials (merger completed in march 2017) thats why its still undiscovered. SLNO has a potential Blockbuster in Phase 3 for the treatment of Prader Willi Syndrome a Rare Disease for which there is no approved treatments . This unknown low float stock which has a terrible low valuation of $24 million could be the next SRPT the stock should be valued way over $100+ million right now for their Phase 3 Program and in the Billion if the outcome of the Phase 3 trial is positive which expected by next year .MYOK and SRPT both rare disease companies hitting Billion Dollar Valuation after Phase 2 results in just 10 patients , you will not find a rare disease company below $100 million valuation with a potential blockbuster in phase 3 that shows how terrible undervalued this stock is .GL

    Soleno therapeutics (SLNO)

    Market Cap $24 Million
    Cash: $8 Million
    Price $0.54

    Shares Out: 47.6 Million ( 36 Million shares held by Insiders & Institutions)

    Initiating Coverage June 26, 2017

    •Company expects to initiate pivotal Phase III clinical trial by year-end 2017; will take approximately 9-12 months to complete

    Soleno Therapeutics, Inc. (Soleno) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is currently advancing its lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, into a Phase III clinical development program at the end of 2017.

    Market Opportunity for PWS is Substantial.

    While the lack of approved treatments for PWS alone make it difficult to assess the market, sales of Pfizer’s (NYSE: PFE)
    Genotrop in (somatropin) can provide some insight despite being indicate for PWS, in addition to, growth failure due to growth hormone deficiency(GHD),Turner syndrome,idiopathic short stature,and small for gestational age.This product achieved its highest revenue in 2008,with worldwide sales of approximately $900 million.While somatropin has been proven to improve growth and body composition, it does not affect the key disease component of hyperphagia and use is associated with substantial risk. Soleno is developing DCCR for the treatment of PWS,to help address the unmet need of this patient population. To assess the potential of DCCR for PWS, we performed a scenario analysis, which indicates that annual sales could be in the range of $1.1 billion given a moderate price point and 50% market penetrance.

    Maxim Group set a $5.00 target price on Capnia, Inc. (NASDAQ:SLNO) in a research note issued to investors on Wednesday, July 5th. The firm currently has a buy rating on the stock.

    VERY Strong Insiders & Institutional ownership :

    Vivo Ventures LLC 16 012 808
    Forward Ventures Services LLC 7 251 728
    Technology Partners 7 050 691
    Aspire Capital Partners LLC 2 791 666
    Ernest Mario, PhD 1 844 328
    Oppenheim Asset Management Services SARL 574 853
    Medical Strategy GmbH 503 305
    Palo Alto Investors LLC 423 738
    Sabby Capital LLC 248 067
    The Bollard Group LLC 192 217
  2. DollarChamp

    DollarChamp Member

  3. DollarChamp

    DollarChamp Member

  4. DollarChamp

    DollarChamp Member

    Analysts Offer Insights on Healthcare Companies: Soleno Therapeutics Inc (NASDAQ: SLNO) and Alexion Pharmaceuticals (NASDAQ: ALXN)

    There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Soleno Therapeutics Inc (NASDAQ: SLNO) and Alexion Pharmaceuticals (NASDAQ: ALXN) with bullish sentiments.

    Soleno Therapeutics Inc (NASDAQ: SLNO)

    Maxim Group analyst Gabrielle Zhou assigned a Buy rating to Soleno Therapeutics Inc (NASDAQ: SLNO) today and set a price target of $5. The company’s shares opened today at $0.62.

    Zhou noted:

    “Soleno today announced the issuance of a new patent (9,757,384) from the U.S. Patent and Trademark Office for the use of pharmaceutical formulations of diazoxide and diazaxide choline (Diazoxide Choline Controlled Release Tablet; DCCR) to reduce aggressive behaviors in patients with Prader-Willi syndrome (PWS) or Smith-Magenis syndrome (SMS).”
  5. DollarChamp

    DollarChamp Member


Share This Page